Article Figures & Data
Tables
Trial Agent Composite kidney outcome Primary or secondary end points Hazard ratio (95% CI) Number needed to treat EMPA-REG OUTCOME8 Empagliflozin Doubling of the serum creatinine level, initiation of kidney replacement therapy, or death from renal disease Secondary 0.54 (0.40–0.75) 194 CANVAS10 Canagliflozin Sustained 40% reduction in eGFR, need for kidney replacement therapy, or death from renal causes Secondary 0.60 (0.47–0.77) 286 DECLARE-TIMI 5811 Dapagliflozin Sustained ≥ 40% reduction in eGFR to < 60 mL/min/1.73 m2, new end-stage kidney disease, or death from renal cause Secondary 0.53 (0.43–0.66) 78 EMPEROR-Reduced9 Empagliflozin Sustained ≥ 40% reduction in eGFR, chronic dialysis, renal transplant, or sustained eGFR < 10–15 mL/min/1.73 m2 Secondary 0.50 (0.32–0.77) 68 CREDENCE12 Canagliflozin End-stage kidney disease, doubling of the serum creatinine level, or death from renal or cardiovascular causes Primary 0.70 (0.59–0.82) 22 DAPA-CKD13 Dapagliflozin Sustained ≥ 50% reduction in eGFR, end-stage kidney disease, or death from renal or cardiovascular cause Primary 0.61 (0.51–0.72) 19 EMPA-KIDNEY14 Empagliflozin End-stage kidney disease, a sustained reduction in eGFR to < 10 mL/min/1.73 m2, renal death, or a sustained decline of ≥ 40% in eGFR Primary Ongoing Ongoing CANVAS = Canagliflozin Cardiovascular Assessment Study; CI = confidence interval; CREDENCE = Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation; DAPA-CKD = Dapagliflozin in Patients With Chronic Kidney Disease; DECLARE-TIMI 58 = Dapagliflozin Effect on Cardiovascular Events; eGFR = estimated glomerular filtration rate; EMPA-KIDNEY = Study of Heart and Kidney Protection With Empagliflozin; EMPA-REG OUTCOME = Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; EMPEROR-Reduced = Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction
